Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. The work represents a key milestone in the company’s chemistry, manufacturing and controls strategy as it advances toward IND-enabling studies and planning for first-in-human clinical evaluation.
Onco said the program will focus on optimizing synthetic processes, improving yield and reproducibility and scaling production of key intermediates required for downstream manufacturing and formulation. The effort will be conducted in collaboration with Dalton Pharma Services and is intended to establish a robust, scalable manufacturing process capable of supporting continued preclinical development, regulatory readiness and future clinical supply requirements.
The announcement is significant as it demonstrates Onco-Innovations’ progress in moving ONC010 from preclinical development toward clinical trials. By focusing on process optimization and scale-up, the company is addressing critical manufacturing challenges that often delay drug development. The collaboration with Dalton Pharma Services brings expertise in pharmaceutical manufacturing, which could enhance the efficiency and reliability of the production process.
ONC010 is designed to target solid tumours, and the company has secured an exclusive worldwide license to patented technology for this indication. The successful development of a robust manufacturing process will be crucial for supplying consistent, high-quality drug substance for toxicology studies and eventual human trials.
Investors and industry observers will be watching as Onco-Innovations progresses toward filing an Investigational New Drug application. The company’s focus on oncology and its innovative approach to cancer treatment position it as a potential player in the competitive oncology space. For more information on the company and its technology, visit https://oncoinnovations.com/.
This development also highlights the importance of manufacturing scale-up in the drug development pipeline. Many promising therapies fail not due to efficacy but because of manufacturing challenges. Onco-Innovations’ proactive approach to addressing these issues early could provide a competitive advantage. The full press release is available at https://nnw.fm/kfFWv.
